Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 15/20 | 0.55 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521174 | 1.00 | CALCRL (0.55) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL3309597 | 0.94 | CALCRL (0.63) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL3309604 | 0.94 | CALCRL (0.63) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL13313782 | 0.89 | CALCRL (0.46) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3309323 | 0.89 | CALCRL (0.48) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL3309312 | 0.89 | CALCRL (0.48) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL13313781 | 0.89 | CALCRL (0.42) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL3316817 | 0.87 | CALCRL (0.48) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL3316819 | 0.87 | CALCRL (0.48) | CALCRLRAMP1CHRM1TNKSPARP1 | |
| SCHEMBL13313770 | 0.85 | CALCRL (0.46) | CALCRLRAMP1CHRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 62/4885CHRM1 42/4885 |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 50/4885CHRM1 32/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 50/4885CHRM1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.